The subscription period for warrants of series 2019/2021 begins today - Regulatory information

25-01-2021   Regulatory press release

Today, on 25 January 2021, the subscription period begins for the warrants of series 2019/2021 that were issued in connection with ADDvise Group AB (publ)'s (“ADDvise” or the “Company”) issue of units in 2019. The subscription period is between January 25 and February 8, 2021. Each warrant of series 2019/2021 entitles to subscribe for one (1) new share of series B in ADDvise at a price of SEK 0.65 per share of series B. If all warrants of series 2019/2021 are exercised, the Company will receive approximately SEK 28 million before issue costs. In order for the warrants not to expire without value, it is required that the holder subscribes for shares no later than February 8, 2021, or alternatively sells the warrants no later than February 4, 2021.

Summarized terms for the warrants of series 2019/2021

Subscription period: January 25, 2021 – February 8, 2021

Size of issue: 43,042,288 warrants of series 2019/2021. Upon full exercise, 43,042,288 shares will be issued and ADDvise receives approximately SEK 28 million before issue costs

Subscription price: SEK 0.65 per series B share

Last day of trading in warrants of series 2019/2021: February 4, 2021

Note that warrants that are not sold no later than February 4, 2021, or alternatively exercised by February 8, 2021, expire worthless. In order for your warrants of series 2019/2021 not to expire, you must subscribe for shares or sell your warrants.

Letter to warrant holders of series 2019/2021 is available at the Company's website, www.addvisegroup.se, and Mangold’s website, www.mangold.se. Full terms for the warrants were included as part of the investment memorandum that was published on January 16, 2019. The investment memorandum and full terms and conditions for the warrants are also available at the above websites.

How to exercise the warrants

Nominee-registered warrants (custody)

Subscription and payment through the exercise of the warrant shall take place in accordance with instructions from the respective nominee. Please contact your trustee for further information.

Directly registered warrants (VP ​​account)

No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at Bolagsverket.

The application form with instructions for payment will be available on the Company's website, www.addvisegroup.se, and on Mangold Fondkommission AB's website, www.mangold.se.

Adviser

Mangold Fondkommission is the financial adviser and Advokatfirman Schjødt is the legal advisor to ADDvise regarding the warrants.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB

Tel: +46 8 5030 1595

E-mail: emissioner@mangold.se

For further information:

Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23
E-mail:
hanna.myhrman@addvisegroup.se

 

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, ca@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

Latest press releases

ADDvise completes the acquisition of MRC Systems FZE

Regulatory

ADDvise Group AB (publ) (”ADDvise”) has today completed the acquisition of all shares in MRC Systems FZE (”MRC”). The signing of the share purchase agreement has been communicated to the market via a press release on 16 February 2021. The total purchase price amounts to USD 8.00 million, of which USD 4.50 million has been…

ADDvise signs Letter of Intent to acquire Medisuite, LLC

Regulatory

ADDvise Group AB (publ) has signed a Letter of Intent with the shareholders of Medisuite, LLC (”Medisuite”) regarding an acquisition of 100 percent of the shares in Medisuite. Medisuite is an American online pharmacy that specializes in medication for men’s health. The prescription medication that is marketed by Medisuite is mainly used for treatment of…

ADDvise Group to redeem its outstanding up to SEK 240,000,000 senior secured callable bonds

Regulatory

ADDvise Group AB (publ) (“ADDvise") hereby announces that ADDvise’s up to SEK 240,000,000 senior unsecured callable floating rate bonds with ISIN SE0010298166 (the "Bonds"), will be redeemed in advance in accordance with Clause 8.3 (Voluntary total redemption (call option)) of the terms and conditions of the Bonds. The redemption date will be 18 June 2021.…